APA Confronts Federal Push to Deprescribe Antidepressants

Health Secretary Robert F. Kennedy Jr. announced a set of policies aimed at encouraging physicians to deprescribe the most widely prescribed class of antidepressants. The announcement came ten days before the American Psychiatric Association’s (APA) annual meeting, where the organization’s leadership publicly rejected governmental interference while signaling willingness to collaborate on clinical guidance.

New York Times

The APA gathering, attended by thousands of psychiatrists, has traditionally been a venue for a variety of protesters—including Scientologists, Falun Gong practitioners, and former patients alleging harm from psychiatric treatments. This year’s meeting was marked by heightened anxiety as the federal deprescribing agenda entered the professional discourse.

New York Times

• Robert F. Kennedy Jr. – U.S. Health Secretary, architect of the deprescribing policies.

New York Times

• Dr. Marketa Wills – Chief Executive Officer of the APA, primary spokesperson at the meeting.

New York Times

• APA President – Unnamed, slated to join a July HHS panel on tapering guidance.

New York Times

• Department of Health and Human Services (HHS) – Convenor of the upcoming clinical guidance panel.

New York Times

The APA’s official stance, articulated by Dr. Wills, emphasized that the association “will never support governmental interference in the practice of medicine.” Nonetheless, the organization accepted an invitation from HHS to join a July panel developing taper-off protocols, with Dr. Wills noting she felt “encouraged” by the invitation and praised the administration for “putting mental health front and center.” The APA president’s participation underscores a cautious engagement with the federal effort.

New York Times

Many physicians at the meeting expressed concern that Kennedy’s statements could lead patients to discontinue antidepressants abruptly, risking relapse. The presence of protestors and the “current of anxiety” among attendees highlighted broader apprehension about oversimplifying complex treatment decisions.

New York Times

• The APA meeting convenes thousands of psychiatrists annually.

New York Times

• The policies target the most widely prescribed class of antidepressants (selective serotonin reuptake inhibitors).

New York Times

The federal push to deprescribe could reshape prescribing practices for a medication class that affects millions of Americans. Balancing patient autonomy, clinical safety, and evidence-based care will be central to any resulting guidelines.

New York Times

The sources do not provide data on the anticipated impact of deprescribing policies, nor do they present differing estimates of potential patient outcomes. Information on how many clinicians intend to alter prescribing habits remains absent.

New York Times

• “We will never support governmental interference in the practice of medicine.” — Dr. Marketa Wills, APA CEO

New York Times

• “We are standing tall for evidence-based care,” — Dr. Marketa Wills, APA CEO

New York Times

• “We are standing tall against stigma, oversimplification, and anything that would move patients further away from the care that they need.” — Dr. Marketa Wills, APA CEO

New York Times

• “putting mental health front and center.” — Dr. Marketa Wills, APA CEO

New York Times

In July, the APA president will join an HHS-convened panel to draft clinical guidance on tapering antidepressants. The outcomes of that panel will likely influence future prescribing standards and the broader debate over federal involvement in psychiatric care.

New York Times